Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Daarsh Innovations Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The current prosecution activity is focused on this single pending matter, reflecting a specific technical focus within the Biotechnology & Pharmaceuticals sector.
Brandon J Fetterolf is the busiest examiner for the company, overseeing 1 pending office action. This 1 action represents the total of 1 pending office action for the portfolio. The concentration in 1 distinct art unit and 1 distinct examiner indicates a streamlined prosecution path. This structure suggests that the company's immediate progress depends on the resolution of this single action.
The 1 pending office action under Brandon J Fetterolf is the sole active matter for the company. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution landscape is straightforward. Success for the current portfolio is tied to this single point of contact. The data shows a very specific administrative and technical scope for the company's active filings in Biotechnology & Pharmaceuticals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 1 | 51.8% | +18.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18430778 | METHODS FOR TREATING VIRAL INFECTIONS | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18430778 | METHODS FOR TREATING VIRAL INFECTIONS | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDaarsh Innovations Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Brandon J Fetterolf has the most, with 1 of Daarsh Innovations Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.